Japan Lifeline Divests Blood Purification Business to JMS
Japan Lifeline Co., Ltd. announced that at the board of directors meeting held on February 26, 2021, it has decided to divest its blood purification business to JMS Co., Ltd. and concluded a business divestment agreement with JMS on the same day.
1. Reason for divestment of business
In 2009, Japan Lifeline acquired Ube Junken Co., Ltd. (later conducted an absorption merger in 2017) to obtain the artificial vascular graft, which it previously distributed as a third-party product. Along with this,
Japan Lifeline developed, manufactured and marketed blood purification products used at ICUs and other facilities. In such a backdrop, JMS, which handles a broad range of products, including infusion, nutrition, and dialysis, submitted a proposal to acquire Japan Lifeline's acute blood purification business in order to further strengthen its business portfolio in areas such as hemodialysis and peritoneal dialysis.
After continued discussions, Japan Lifeline decided to divest this business in order to focus its management resources on the cardiovascular space where it has already established its presence, and the gastrointestinal space where it has been developing new businesses. With this business divestment, Japan Lifeline expects that it will be able to accelerate the development and introduction of new products, enabling a further growth in profitability.
2. Overview of business divestment
(1) Target of business divestment
Blood purification business (development, manufacture and sale of blood purification equipment and blood circuits)
(2) Revenue from divested business 914 million yen (the year ended March 2020)
Hiroaki Okukubo, President and Representative Director
(4)Business Descriptions
Manufacture, sale, export and import of medical devices and pharmaceuticals
(5)Capital (as at end of March 2020)
7,411 million yen
(6)Foundation
June 12, 1965
(7)Consolidated net assets (as at end of March 2020)
32,470 million yen
(8)Consolidated gross assets (as at end of September 2020)
66,567 million yen
(9)Major shareholders and their holding ratios (as at end of September 2020)
Kaneka Corporation 10.12%, Tsuchiya Memorial Medical Foundation 7.78%, The Master Trust Bank of Japan, Ltd. (Trust) 4.72%, Saeko Tsuchiya 4.12%, Senjukai, Social Welfare Organization 4.09% etc.
(10)Relationship with Japan Lifeline
Capital relationship: None
Human resource relationship: None
Transaction relationship: Japan Lifeline has a transaction relationship with JMS.
4. Schedule
Execution of business divestment agreement: February 26, 2021 Date of business divestment: April 1, 2021
5. Future Outlook
Japan Lifeline expects that this business divestment has no material impact on the consolidated results for the year ending March 31, 2021.
Attachments
Original document
Permalink
Disclaimer
JLL - Japan Lifeline Co. Ltd. published this content on 26 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 February 2021 06:12:06 UTC.
Japan Lifeline Co., Ltd. is a Japan-based company mainly engaged in the import, manufacture and sale of cardiac circulators and other medical devices. The Company is mainly engaged in the production of rhythm devices, electrophysiological (EP) and ablations, surgical products and intervention products. The rhythm devices include cardiac pacemakers, implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and other rhythm devices. The EP and ablations include EP catheters for cardiac arrhythmia examination, ablation catheters for arrhythmia treatment and other EP and ablations. The surgical products include prosthetic heart valves and annuloplasty rings for heart disease surgical treatment, vascular grafts, open stent grafts and stent grafts for aortic disease treatment, as well as other surgical products. The intervention products include balloon catheters, guide wires, penetration catheters and other intervention products.
JAPAN LIFELINE CO., LTD. 
